Molecular Docking and 3D-Pharmacophore Modeling to Study the Interactions of Chalcone Derivatives with Estrogen Receptor Alpha

Muchtaridi Muchtaridi 1,*, Hasna Nur Syahidah 1, Anas Subarnas 2, Muhammad Yusuf 3, Sharon D. Bryant 4 and Thierry Langer 5

1 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jln. Raya Bandung-Sumedang KM. 21, Jatinangor 45363, West Java, Indonesia; hasnans20@gmail.com
2 Department of Pharmacology, Faculty of Pharmacy, Universitas Padjadjaran, Jln. Raya Bandung-Sumedang KM. 21, Jatinangor 45363, West Java, Indonesia; aasubarnas@yahoo.co.id
3 Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jln. Raya Bandung-Sumedang KM. 21, Jatinangor 45363, West Java, Indonesia; m.yusuf@unpad.ac.id
4 Inte: Ligand GmbH, Mariahilferstrasse 74B/11, A-1070 Vienna, Austria; bryant@inteligand.com
5 Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria; thierry.langer@univie.ac.at
* Correspondence: muchtaridi@unpad.ac.id; Tel.: +62-22-7796200

Received: 21 August 2017; Accepted: 15 October 2017; Published: 16 October 2017

Abstract: Tamoxifen is the most frequently used anti-estrogen adjuvant treatment for estrogen receptor-positive breast cancer. However, it is associated with an increased risk of several serious side-effects, such as uterine cancer, stroke, and pulmonary embolism. The 2′,4′-dihydroxy-6-methoxy-3,5-dimethylchalcone (ChalcEA) from plant leaves of Eugenia aquea, has been found to inhibit the proliferation of MCF-7 human breast cancer cells in a dose-dependent manner, with an IC50 of 74.5 µg/mL (250 µM). The aim of this work was to study the molecular interactions of new ChalcEA derivatives formed with the Estrogen Receptor α (ERα) using computer aided drug design approaches. Molecular docking using Autodock 4.2 was employed to explore the modes of binding of ChalcEA derivatives with ERα. The 3D structure-based pharmacophore model was derived using LigandScout 4.1 Advanced to investigate the important chemical interactions of the ERα-tamoxifen complex structure. The binding energy and the tamoxifen-pharmacophore fit score of the best ChalcEA derivative (HNS10) were −12.33 kcal/mol and 67.07 kcal/mol, respectively. The HNS10 interacted with Leu346, Thr347, Leu349, Ala350, Glu353, Leu387, Met388, Leu391, Arg394, Met421, and Leu525. These results suggest that the new ChalcEA derivatives could serve as the lead compound for potent ERα inhibitor in the fight against breast cancer.

Keywords: chalcone; molecular docking; structure-based 3D pharmacophore modeling; anti-breast cancer; estrogen receptor α; MCF-7

1. Introduction

Breast cancer accounts for more than 1.2 million new cases and 500,000 deaths annually. It is the leading cause of cancer death among females (23% of total cancer and 14% of cancer mortality cases) [1]. Mortality in women due to this cancer in both developed (189,000 deaths) and emerging (269,000 deaths) economies was reported to reach 15.5% and 12.7% of total breast cancer cases, respectively in 2012 [2]. In 2013, the prevalence of breast cancer in Indonesia was reported to afflict 1.4% of the total population (approximately 347,792 persons) [3].

Pharmaceuticals 2017, 10, 81; doi:10.3390/ph10040081 www.mdpi.com/journal/pharmaceuticals
Estrogen plays a critical role in the growth and development of bone, breast, and uterine pathology. There are two subtypes of estrogen receptor, ER\textsubscript{α} (Estrogen Receptor-α) and ER\textsubscript{β} (Estrogen Receptor-β). ER\textsubscript{α} plays a role in cell proliferation and has been found in the endometrial, breast cancer and ovarian stromal cells, as well as in the hypothalamus [4]. The most commonly used anti-estrogen adjuvant treatment for ER\textsubscript{α}-positive (ER\textsubscript{α}+) premenopausal women is tamoxifen, a selective estrogen receptor modulator (SERM). The active metabolite of tamoxifen is 4-hydroxytamoxifen (4-OHT) [5]. Tamoxifen is also often prescribed for postmenopausal patients with ER\textsubscript{α}+ tumors. It acts as an antagonist to ER\textsubscript{α} and inhibits its signaling pathway in ER\textsubscript{α}+ breast cancer cells. Tamoxifen therapy significantly reduces the risk of breast cancer recurrence. The tamoxifen-bound ER complex inhibits the genes from being switched on by estrogen, leading to the prevention of the estrogenic effects responsible for cancer cell proliferation [6].

Despite the obvious benefit of tamoxifen in breast cancer treatment, this drug also has serious risks. For example, the risk of endometrial malignancy and hyperplasia varies from 1.5- to 6.9-fold [7] after cumulative and long duration usage [8] due to its agonistic effect in the uterus. In addition, the potential for endometrial cancer increased significantly with overweight postmenopausal females. To further complicate matters, many ER\textsubscript{+} patients, regardless of high levels of ER, demonstrated intrinsic resistance to hormonal therapies. Thus, alternative treatments are needed.

One promising natural anti-breast cancer adjuvant compound is chalcone, a flavonoid group secondary metabolite found in many plants. The 2′,4′-dihydroxy-6-methoxy-3,5-dimethylchalcone (ChalcEA) from the leaves of Eugenia aquea inhibited the cell proliferation of MCF-7 human breast cells, in a dose-dependent manner, with an IC\textsubscript{50} of 74.5 \(\mu\)g/mL (250 \(\mu\)M). It has been hypothesized to promote apoptosis via the activation of poly(adenosine diphosphate-ribose)polymerase (PARP). Further investigations have provided a basis for its use in breast cancer disease management [7]. However, its IC\textsubscript{50} value was considered as a moderate level of inhibition compared to tamoxifen [8]. Therefore, further efforts to improve the inhibitory activity of ChalcEA through structural modifications guided by computer-aided drug design (CADD) methodologies, such as molecular docking method and 3D-pharmacophore modeling, were explored in this study.

The biological activity of a compound defined by the affinity of a small-molecule ligand towards the macromolecular receptor can be explored using in silico methods and compared to the experimental methods. Molecular docking scoring functions can compute binding affinities that are useful for predicting bioactive poses of compounds and prioritizing compounds for experimental assessment. These structure-based drug design methods are useful for drug discovery research. The molecular docking approach can be used to model an interaction between a small molecule (ligand) and protein at the atomic level. The docking process involves two basic steps: prediction of multiple structural conformations in a binding pocket (pose), and scoring the pose in order to rank the multiple solutions [9].

A pharmacophore represents the key interaction features of a molecule responsible for eliciting or blocking biological activity [10]. 3D-pharmacophore models not only describe the chemical feature types but also define the 3D geometry of the features of a bioactive compound. Ligand-based (LB) pharmacophore modeling involves a set of known active molecules without including information from the macromolecular target. Structure-based (SB) pharmacophore models are composed of features derived from interactions between the binding pocket and the ligand and require a target ligand complex binding pocket. Pharmacophore models resulting from SB and LB approaches are used to understand the key interaction features of a set of active molecules and how a bioactive ligand interacts with the target-binding site. The 3D-models can be used to search for bioactive molecules using virtual screening methods or to provide medicinal chemistry decision support during hit expansion and lead optimization [11]. The pharmacophore modeling study involved the evaluation of the key pharmacophore interaction features of 4-OHT, ChalcEA and the derivatives reported herein.
2. Results

The X-ray derived structure of ERα in complex with 4-OHT (PDB code: 3ERT) was selected for molecular docking studies of ChalcEA due to good parameters for experimental resolution (1.9 Å), R-value free and R-value work of 0.262 and 0.229, respectively [12]. The interactions derived from the X-ray derived structure revealed that 4-OHT formed hydrophobic interactions predominantly with the butenyl group and aromatic rings, a positive ionizable interaction with primary the tertiary amine nitrogen and hydrogen bond interactions with the phenoxy and hydroxyl oxygens (Figure 1a,b).

Before performing the molecular docking simulation, we first validated our docking method by extracting 4-OHT from the crystallographic ERα structure and docking it into the binding site to verify that the docking program could reproduce the antagonist bioactive conformation of 4-OHT. The best-docked ligand conformation shown in Figure 2 had a root mean square deviation (RMSD) of 0.893 Å compared to the original X-ray derived conformation.

The ligand binding domain (LBD) of ERα is mainly a hydrophobic cavity composed of residues from helices 3, 6, 7, 8, 11 and 12 [13]. Helix-12 of the ER (residues 536–544) plays a major role in determining the agonist or antagonist activity of a ligand. When 4-OHT, an antagonist, binds to the ERα LBD, helix-12 occludes the co-activator recognition groove resulting in antagonist activity. This phenomenon occurs due to the absence of hydrogen bonding with His524 when 4-OHT is bound. In contrast, hydrogen bonding occurs with His524 and the ER agonist estradiol [13].

![Figure 1. (a) Pharmacophore-Molecular Docking Based of 4-OHT with ERα derived from the X-ray derived structure (PDB code: 3ERT). Hydrophobic, positive ionizable, hydrogen bond donor and acceptor interactions are depicted as yellow spheres, blue star, green and red arrows, respectively. (b) The 2D-depiction illustrates a hydrophobic pocket with hydrophobic interactions with the binding site residues. Interactions derived and depicted using LigandScout 4.1 Advanced. Hydrogen atoms on the ligand and excluded volumes (restricted areas that define the shape of the binding pocket) are not displayed.](image1)

![Figure 2. Best docked pose of 4-hydroxytamoxifen (4-OHT) with estrogen receptor-alpha (ERα) using AutoDock 4.2.](image2)
2.1. Modification of ChalcEA Derivatives

The best-docked conformation of ChalcEA (Figure 3) within the LBD of ERα revealed hydrogen bonds with the 2′ and 4′ hydroxyl groups, whereas the carbonyl group did not form any interaction. Comparison of the predicted binding poses of ChalcEA and 4-OHT showed that two aromatic rings from each molecule were positioned similarly in the LBD (Figure 4).

![Figure 3. Best docked pose of ChalcEA with ERα. One hydrogen bond donor, one hydrogen acceptor and three hydrophobic (pi-alkyl) interactions are represented with green, red, and black, colored dashed lines, respectively. This interaction was visualized by LigandScout 4.1.](image1)

However, the dimethylaminoethoxy group of 4-OHT extended further than the carbonyl group of ChalcEA. This difference might account for the higher computed free energy of binding (ΔG) of ChalcEA (−8.23 kcal/mol) compared to a ΔG of −11.04 kcal/mol for 4-OHT.

![Figure 4. Overlay of the docked pose of ChalcEA (gray) and 4-hydroxy-tamoxifen (4-OHT) (blue) in the binding site of estrogen receptor alpha (ERα). Hydrogen bond and pi-alkyl interactions are represented in green and pink colored dashed lines, respectively.](image2)
Therefore, the design of ten new ChalcEA derivatives shown in Table 1 focused on modifications at the position of the carbonyl group and dihydroxy substituted aromatic ring. All modifications were guided by the key ERα interactions with 4-OHT (Figure 1), and Lipinski’s Rule of Five (molecular weight less than 500, log P or coefficient partition between −5 and 5, less than five hydrogen bond donors, and less than ten hydrogen bond acceptors [14] (Table 2). Therefore, we aimed to increase the hydrophobicity around the dihydroxyl substituted aromatic ring, by replacing hydroxyl groups with methoxy groups and introducing extended substitutions at the R5 position of ChalcEA (Table 1).

**Table 1.** Derivatives of 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone (ChalcEA).

| No. | Molecule Name | R1  | R2  | R3  | R4  | R5  |
|-----|---------------|-----|-----|-----|-----|-----|
| 1   | HNS1          | OCH3| H   | H   | H   | -   |
| 2   | HNS2          | H   | H   | H   | H   |     |
| 3   | HNS3          | H   | H   | H   | H   |     |
| 4   | HNS4          | H   | H   | H   | H   |     |
| 5   | HNS5          | H   | H   | H   | H   |     |
| 6   | HNS6          | H   | H   | H   | H   | -   |
| 7   | HNS7          | CH3 | H   | -   | H   |     |
| 8   | HNS8          | H   | H   | H   | H   |     |
| 9   | HNS9          | CH3 | OH  | H   | OH  |     |
| 10  | HNS10         | -   | H   | -   | H   |     |
Table 2. Computed standard properties of ChalcEA derivatives based on Lipinski's Rule of Five. HB indicates hydrogen bond.

| No. | Derivative Name | Molecular Weight (g/mol) | Log P | Number of HB Donors | Number of HB Acceptors |
|-----|-----------------|---------------------------|-------|---------------------|------------------------|
| 1   | HNS1            | 284.355                   | 3.60  | 1                   | 3                      |
| 2   | HNS2            | 374.501                   | 2.27  | 3                   | 4                      |
| 3   | HNS3            | 328.408                   | 4.03  | 2                   | 4                      |
| 4   | HNS4            | 330.484                   | 3.07  | 3                   | 3                      |
| 5   | HNS5            | 330.424                   | 3.82  | 3                   | 4                      |
| 6   | HNS6            | 399.531                   | 4.22  | 2                   | 4                      |
| 7   | HNS7            | 372.529                   | 2.88  | 2                   | 3                      |
| 8   | HNS8            | 427.585                   | 5.00  | 2                   | 4                      |
| 9   | HNS9            | 436.572                   | 3.75  | 4                   | 4                      |
| 10  | HNS10           | 450.599                   | 4.05  | 3                   | 4                      |

The docking results of the ten derivatives, HNS1-HNS10 is summarized in Table 3.

Table 3. Results of molecular docking simulation of ChalcEA derivatives in ligand binding domain of estrogen receptor alpha (ERα).

| No. | Molecule Name | Chemical Formula | \(\Delta G\) (kcal/mol) | Number in Cluster | Calculated Ki (nM) | Interactions with Amino Acids | van der Waals (Hydrophobic) |
|-----|---------------|------------------|--------------------------|-------------------|-------------------|------------------------------|----------------------------|
| 1   | HNS1          | C_{13}H_{10}O_{3} | -9.30                    | 35                | 153.41            | Glu353, Arg394               | Leu525, Met421, Leu387, Ala350, Leu349 |
|     |               |                  |                          |                   |                   |                              |                            |
| 2   | HNS2          | C_{22}H_{20}NO_{4} | -9.25                    | 29                | 66.92             | Leu346, Leu387               | Gly521, Val418, Leu346, Met343, Met421, Met343, Asp351, Thr347 |
|     |               |                  |                          |                   |                   |                              |                            |
| 3   | HNS3          | C_{22}H_{20}NO_{4} | -9.01                    | 64                | 249.32            | Gly420                       | Leu346, Glu333, Arg394, Leu349, Ala350, Leu525 |
|     |               |                  |                          |                   |                   |                              |                            |
| 4   | HNS4          | C_{20}H_{20}NO_{3} | -9.26                    | 53                | 162.64            | Thr347, Leu346, Glu353, Arg394 | Leu349, Ala350, Leu387, Ala350, Thr347, Trp383, Arg349, Leu391, Ala350, Leu349, Met388, Leu421, His524, Leu525 |
|     |               |                  |                          |                   |                   |                              |                            |
| 5   | HNS5          | C_{20}H_{20}O_{4}  | -9.44                    | 75                | 120.52            | Thr347, Leu346, Glu353, Arg394 | Leu387, Ala350, Leu349, Ala349, Leu391, Met388, Leu421, Leu525 |
|     |               |                  |                          |                   |                   |                              |                            |
| 6   | HNS6          | C_{14}H_{13}NO_{4} | -9.76                    | 30                | 70.51             | Leu346, Glu333, Arg394       | Leu387, Leu349, Ala350, Leu349, Met388, Leu391 |
|     |               |                  |                          |                   |                   |                              |                            |
| 7   | HNS7          | C_{21}H_{13}NO_{3} | -9.93                    | 49                | 52.67             | Arg394, Leu387, Thr347       | Leu346, Leu349, Ala350, Asp351, Leu525, Met421, Leu421, Leu525, Leu391 |
|     |               |                  |                          |                   |                   |                              |                            |
| 8   | HNS8          | C_{26}H_{30}NO_{4} | -10.96                   | 43                | 9.27              | Glu353                       | Met421, Leu525, Met388, Leu391, Leu346, Leu349, Leu387, Ala350, Thr347, Thr383 |
|     |               |                  |                          |                   |                   |                              |                            |
| 9   | HNS9          | C_{27}H_{31}NO_{4} | -12.15                   | 83                | 1.25              | Leu346, Glu333, Arg394, Leu387 | Met421, Leu525, Thr347, Ala350, Leu349, Leu391, Ala350, Asp351, Thr347, Thr383 |
|     |               |                  |                          |                   |                   |                              |                            |
| 10  | HNS10         | C_{28}H_{33}NO_{4} | -12.33                   | 42                | 0.91              | Leu346, Glu333, Arg394       | Met421, Leu525, Thr347, Ala350, Leu349, Leu391, Ala350, Asp351, Thr347, Thr383 |


The ΔG calculated the free energy of binding ranged from $-12.33$ to $-9.30$ kcal/mol. The best pose from each derivative exhibited better ΔG than the best-docked pose of ChalcEA ($-8.23$ kcal/mol). Seven out of ten ChalcEA derivatives formed a hydrogen bond with Arg394, similar to the 4-OHT.

### 2.2. Structure-Based 3D Pharmacophore Modeling

The 3D structure-based pharmacophore model was created using LigandScout 4.1 Advanced. LigandScout automatically derives key chemical features, such as hydrogen bond donors and acceptors, hydrophobic, positive and negative ionizable, aromatic interactions along with their 3D-geometries of a bioactive molecule. During virtual screening, it aligns ligands based on their pharmacophore features in 3D space using an advanced algorithm [15]. The validation of the structure-based 3D pharmacophore model involved virtual screening of 626 molecules active at ER$\alpha$ and 20,773 ER$\alpha$ decoys taken from the enhanced Database of Useful Decoys (DUDe) using the derived 3D-model. The early enrichment factor (EF$\text{pre}$) was 32.4 with an excellent AUC (area under the ROC curve) value of 1.00 (Figure 5) indicating that the pharmacophore model was able to distinguish successfully true active from decoy ER$\alpha$ molecules in accordance with methods described by Kirchmair et al. [16].

The key pharmacophore interaction features of 4-OHT and ER$\alpha$ included hydrophobic, a positive ionizable and hydrogen bond donor and acceptors (Figure 1). Virtual screening results of ChalcEA the ten derivatives are reported in Table 4 in the form of a pharmacophore fit score which measures the geometric fit of the features of a molecule to the 3D-structure-based pharmacophore model. A higher fit score indicates a better fit to the model, and therefore molecules that fit to the pharmacophore model should also show activity at ER$\alpha$ because not all of the features of the model could be matched any two features could be omitted during the virtual screening process. In this case, features that could not be matched would result in lower pharmacophore fit scores. Interestingly, the pharmacophore fit scores of all of the derivatives (46.61 to 67.07) were all higher than the parent compound, ChalcEA (45.90). HNS9 and HNS10 had the best pharmacophore fit scores meaning that their chemical features aligned best to the features of the 4-OHT SB pharmacophore model. Moreover, a strong correlation between pharmacophore fit scores and docking scores was indicated from its R-squared ($R^2 = 0.75$).

![Figure 5](image-url). Receiver operating characteristic (ROC) curve validation of the 3D structure-based pharmacophore model using a set of 626 estrogen receptor alpha active and 20,773 decoy molecules.
Table 4. LigandScout pharmacophore fit score of ChalcEA derivatives retrieved using the 3D-structure-based pharmacophore derived from 4-hydroxytamoxifen (4-OHT) bound to the estrogen receptor alpha (ERα). A higher fit score indicates a better geometric alignment of the features of the compound to the 3D-pharmacophore model. The docking score of each compound is provided for comparison.

| No. | Compound | Pharmacophore-Fit Score | Docking Score (kcal/mol) |
|-----|----------|-------------------------|--------------------------|
| 1   | ChalcEA  | 45.90                   | −8.23                    |
| 2   | HNS1     | 46.76                   | −9.30                    |
| 3   | HNS2     | 46.62                   | −9.25                    |
| 4   | HNS3     | 56.57                   | −9.01                    |
| 5   | HNS4     | 46.61                   | −9.26                    |
| 6   | HNS5     | 56.68                   | −9.44                    |
| 7   | HNS6     | 55.33                   | −9.76                    |
| 8   | HNS7     | 55.00                   | −9.93                    |
| 9   | HNS8     | 56.20                   | −10.96                   |
| 10  | HNS9     | 66.50                   | −12.15                   |
| 11  | HNS10    | 67.07                   | −12.33                   |

2.3. Interpretation of Molecular Docking Results and Pharmacophore Modeling

HNS9 and HNS10 displayed the best pharmacophore fit scores compared to the other derivatives and ΔG free energy of binding (−12.01 kcal/mol and −12.33 kcal/mol, respectively) better than 4-OHT (−11.04 kcal/mol). HNS9 formed ten hydrophobic contacts with Met421, Leu525, Met343, Asp351, Thr347, Ala350, Leu349, Leu391, Leu384, and Met388, and four hydrogen bonds with Leu346, Glu353, Arg394, and Leu387 (Figure 6a), whereas HNS10 formed eight hydrophobic contacts with Met421, Leu525, Thr347, Ala350, Leu387, Leu349, Met388, and Leu391, and three hydrogen bonds with Leu346, Glu353, and Arg394.

Both HNS9 and HNS10 formed hydrogen bonds with Leu346, Glu353, and Arg394 (Figure 6b). The formation of hydrogen bonds with Glu353 and Arg394 is essential for binding to ERα [17], which is...
in agreement with the previous docking studies involving chalcone [18]. Hydrophobic interactions also contributed to the overall binding of ChalcEA derivatives with ERα. The aromatic rings of HNS9 and HNS10 formed CH-pi hydrophobic interactions with Ala350, Met421, and Leu525 (Figure 6).

Figure 7 shows that the hydroxyl groups in ortho position on HNS9 hindered the complete mapping with all four hydrophobic features of 4-OHT (Figure 7a). In contrast, the meta position of hydroxyl groups on the aromatic ring of HNS10 enabled a better alignment with the center of the hydrophobic features, thus resulting in a higher fit score (Figure 7b).

![Figure 7](image)

**Figure 7.** Fit of the (a) HNS9 (b) HNS10 to the structure-based pharmacophore model derived from 4-OHT with ERα from PDB code: 3ERT. The models were generated using LigandScout 4.1 Advanced. Virtual screening was performed leaving at least two features out. The ligands fit six of the eight features and all of the excluded volumes.

### 3. Discussion

To address the issue related the agonistic effect of 4-OHT in the uterus [19], Elwood et al. reported that a shorter distance between Asp351 would likely to decrease the agonistic effect of 4-OHT to uterus [20]. We measured and compared the distances of the dimethylaminoethoxy groups of 4-OHT, HNS9, and HNS10 to be 3.3 Å, 3.2 Å, and 2.8 Å respectively, indicating that HNS9 and HNS10 might form stronger interactions with Asp351 and potentially a decreased agonistic effect in the uterus. However, further theoretical studies related to the agonistic effects of 4-OHT would need to be conducted to verify the hypothesis that the modified ChalcEA might not have the same adverse effects as observed with tamoxifen. Future studies will elaborate the synthesis and biological evaluation of the best predicted ChalcEA derivatives to assess their interaction with ERα and their potential for modulating anti-breast cancer activity.

### 4. Materials and Methods

The general scheme of methods in this work is presented in Figure 8.
4.1. Molecular Docking Simulation

The positive control system was the X-ray crystallography derived ERα in complex with 4-OHT taken from Protein Data Bank (PDB ID: 3ERT) [21]. The macromolecule and ligand structures were separated using Discovery Studio Visualizer 4.0. 3D structures of ligands were prepared and optimized by Hyperchem (HyperCube, Inc., Gainesville, FL, USA) and LigandScout 4.1 Advanced (Inte:Ligand GmbH, Vienna, Austria). The molecular docking simulation methods were carried out according to a previously reported study [13]. All ligands and the ERα receptor were prepared for docking using AutoDockTools (ADT) 1.5.6. The ligands and receptor were protonated. The default Kollman charges [22] and solvation parameters were allocated to the protein atoms. Gasteiger charges were added to each ligand atom [23]. A grid box comprised of $40 \times 40 \times 40$ points spaced by 0.375 Å was centered on the ERα active site ($x = 30.282$, $y = -1.913$, and $z = 24.207$). The pre-calculated binding affinity of each ligand’s atom type was prepared using Autogrid [24].

AutoDock 4.2 was utilized for the molecular docking simulation. The parameters of the Lamarckian Genetic Algorithm (LGA) were: 100 runs, elitism of 1, the mutation rate of 0.02, the population size of 150, a crossover rate of 0.80 and 5,000,000 energy evaluations [25]. The resulting docked conformations were clustered using a root-mean-square deviation (RMSD) tolerance of 1.0 Å. The ligand conformation with the lowest free energy of binding ($\Delta G$), chosen from the most favored cluster, was selected for the further analysis. The docking results were visualized using Accelrys Discovery Studio Visualizer 4.0, and the ligand-interaction features for each pose within the binding pocket were determined automatically using LigandScout Advanced 4.1.

4.2. Structure-Based 3D-Pharmacophore Modeling

A 3D SB-pharmacophore model was derived automatically from the X-ray derived structure of ERα in complex with 4-OHT, (PDB code: 3ERT) using Ligandscout 4.1 Advanced [15]. The resulting 3D-interaction feature model was validated for its ability to distinguish true active compounds from decoys by screening a set of 626 known active and 20,773 decoy compounds obtained from the enhanced Database of Useful Decoys (DUDe: http://dude.docking.org) [26]. The libraries from DUDe were converted into 3D multi-conformational databases for virtual screening using the LigandScout 4.1 Advanced algorithm, idbgen, which computes conformations and annotates each conformation with pharmacophore features. All of the ChalcEA derivatives were screened virtually using the validated 3D-SB pharmacophore model and the LigandScout 4.1 Advanced VS algorithm, iscreen with a maximum of 2 omitted features to identify and rank ligands in the library that could fit the geometry and features of the 3D-model. The pharmacophore fit score measured the fit of features of each hit compound to the pharmacophore model features and was used to rank the hit molecules retrieved by the pharmacophore model.

Figure 8. The general scheme of methodologies in the present work.
5. Conclusions

Essential interactions of ChalcEA derivatives with ERα involves hydrogen bond and hydrophobic non-covalent features. The best derivatives among the ten designed candidates identified using the molecular docking and pharmacophore modeling studies were HNS9 and HNS10. HNS9 contained a modification at R1 (methyl), R2 (hydroxyl), R4 (hydroxyl) and R5 (dimethylaminoethoxyphenyl), while HNS10 only at the R5 with a similar group with HNS9. Both HNS9 and HNS10 still complied the Lipinski’s Rule of Five. The free energy of binding (ΔG) of HNS9 and HNS10 were −12.15 kcal/mol and −12.33 kcal/mol, respectively. Both contained key interaction features that could be geometrically aligned with a validated SB pharmacophore model of 4-OHT (pharmacophore fit score of 67.07). The two derivatives represent rational computationally designed compounds prioritized for further biological investigation and hit optimization targeted for future development of chalcone based derivatives as new anti-breast cancer therapies with ERα inhibitor activity and better side effect profiles compared to tamoxifen.

Acknowledgments: This study was supported by The Directorate General of Higher Education of The Ministry of Research and Technology of Indonesia through International Research Collaborations and Publications Grants 2016.

Author Contributions: Hasna Nur Syahidah and Muhammad Yusuf performed the experiments. Muchtaridi Muchtaridi and Anas Subarnas conceived and designed the experiments. Muhammad Yusuf, Hasna Nur Syahidah, and Sharon D. Bryant analyzed the data. Hasna Nur Syahidah, Muhammad Yusuf, and Muchtaridi wrote the paper. Sample Availability: Samples of the compounds HNS9 and HNS10 are available from the authors.

Conflicts of Interest: The authors declare no conflict of interests.

References
1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90. [CrossRef] [PubMed]
2. Cardoso, F.; Harbeck, N.; Fallowfield, L.; Kyriakides, S.; Senkus, E.; Group, E.G.W. Locally recurrent or metastatic breast cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23, 11–19. [CrossRef] [PubMed]
3. Budijanto, D. Infodatin-Breast Cancer. Available online: http://tinyurl.com/ycx6sgxh (accessed on 11 June 2015).
4. Levin, E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 2005, 19, 1951–1959. [CrossRef] [PubMed]
5. Sanyakamdhorn, S.; Agudelo, D.; Bekale, L.; Tajmir-Riahi, H.A. Targeted conjugation of breast anticancer drug tamoxifen and its metabolites with synthetic polymers. Coll. Surf. B: Biointerfaces 2016, 145, 55–63. [CrossRef] [PubMed]
6. Chang, M. Tamoxifen resistance in breast cancer. Biomol. Ther. 2012, 20, 256–267. [CrossRef] [PubMed]
7. Subarnas, A.; Diatini, A.; Abdulah, R.; Zuhrotun, A.; Hadisaputri, Y.E.; Puspitasari, I.M.; Yamazaki, C.; Kuwano, H.; Koyama, H. Apoptosis induced in mcf-7 human breast cancer cells by 2’,4’-dihydroxy-6-methoxy-3,5-dimethylchalcone isolated from eugenia aquae burm f. Leaves. Oncol. Lett. 2015, 9, 2303–2306. [CrossRef] [PubMed]
8. Cohen, L.H.; Remley, M.J.; Raunig, D.; Vaz, A.D. In vitro drug interactions of cytochrome p450: An evaluation of fluorogenic to conventional substrates. Drug Metab. Dispos. 2003, 31, 1005–1015. [CrossRef] [PubMed]
9. Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 2011, 7, 146–157. [CrossRef] [PubMed]
10. Guner, O.F.; Bowen, J.P. Setting the record straight: The origin of the pharmacophore concept. J. Chem. Inf. Model. 2014, 54, 1269–1283. [CrossRef] [PubMed]
11. Kalyaanamorthy, S.; Chen, Y.P. Structure-based drug design to augment hit discovery. Drug Discov. Today 2011, 16, 831–839. [CrossRef] [PubMed]
12. Smyth, M.S.; Martin, J.H. X-ray crystallography. Mol. Pathol. 2000, 53, 8–14. [CrossRef] [PubMed]
13. Muchtaridi, M.; Yusuf, M.; Diantini, A.; Choi, S.B.; Al-Najjar, B.O.; Manurung, J.V.; Subarnas, A.; Achmad, T.H.; Wardhani, S.R.; Wahab, H.A. Potential activity of fevicordin-a from *Phaleria macrocarpa* (Scheff) boerl. Seeds as estrogen receptor antagonist based on cytotoxicity and molecular modelling studies. *Int. J. Mol. Sci.* 2014, **15**, 7225–7249. [CrossRef] [PubMed]

14. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. *Drug Discov. Today Technol.* 2004, **1**, 337–341. [CrossRef] [PubMed]

15. Wolber, G.; Langer, T. Ligandscout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. *J. Chem. Inf. Model.* 2005, **45**, 160–169. [CrossRef] [PubMed]

16. Kirchmair, J.; Distinto, S.; Markt, P.; Schuster, D.; Spitzer, G.M.; Liedl, K.R.; Wolber, G. How to optimize shape-based virtual screening: Choosing the right query and including chemical information. *J. Chem. Inf. Model.* 2009, **49**, 678–692. [CrossRef] [PubMed]

17. Wang, Z.; Li, Y.; Ai, C.; Wang, Y. In silico prediction of estrogen receptor subtype binding affinity and selectivity using statistical methods and molecular docking with 2-arylnaphthalenes and 2-arylquinolines. *Int. J. Mol. Sci.* 2010, **11**, 3434. [CrossRef] [PubMed]

18. Vedavalli, S.; Srinivasan, T.; Suhitha, S.; Velmurugan, D.; Kandaswamy, M. Molecular docking study of chalcone derivative with human estrogen receptor as target protein and its anti-cancer activity against hepg2 cells. *Int. J. Pharm. Tech. Res.* 2014, **6**, 1580–1583.

19. Jensen, E.V.; Jordan, V.C. The estrogen receptor: A Model for Molecular Medicine. *Clin. Cancer Res.* 2003, **9**, 1980–1989. [PubMed]

20. Cano, A.; Hermenegildo, C. The endometrial effects of serms. *Hum. Reprod. Update* 2000, **6**, 244–254. [CrossRef] [PubMed]

21. Shiau, A.K.; Barstad, D.; Loria, P.M.; Cheng, L.; Kushner, P.J.; Agard, D.A.; Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 1998, **95**, 927–937. [CrossRef]

22. Scott, J.; Weiner, S.J.; Kollman, P.A.; Case, D.A.; Singh, U.C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. A new force field for molecular mechanical simulation of nucleic acids and proteins. *J. Am. Chem. Soc.* 1984, **106**, 765–784.

23. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity—A rapid access to atomic charges. *Tetrahedron* 1980, **36**, 3219–3228. [CrossRef]

24. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.* 1998, **19**, 1639–1662. [CrossRef]

25. Ikram, N.K.K.; Durrant, J.D.; Muchtaridi, M.; Zalaludin, A.S.; Purwitasari, N.; Mohamed, N.; Rahim, A.S.A.; Lam, C.K.; Normi, Y.M.; Rahman, N.A. A virtual screening approach for identifying plants with anti h5n1 neuraminidase activity. *J. Chem. Inf. Model.* 2015, **55**, 308–316. [CrossRef] [PubMed]

26. Mysinger, M.M.; Carchia, M.; Irwin, J.J.; Shoichet, B.K. Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking. *J. Med. Chem.* 2012, **55**, 6582–6594. [CrossRef] [PubMed]